ArriVent BioPharma (AVBP) Shares Outstanding (Diluted Average) (2023 - 2026)

ArriVent BioPharma has disclosed Shares Outstanding (Diluted Average) across 4 years of filings, most recently posting $45.1 million for Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $45.1 million, up 32.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $45.1 million (up 32.95% YoY), and the FY2025 annual result was $38.5 million, up 22.22% from the prior year.
• Shares Outstanding (Diluted Average) came in at $45.1 million for Q1 2026 at ArriVent BioPharma, up from $38.5 million in the prior quarter.
• In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $45.1 million in Q1 2026 to a low of $1.3 million in Q1 2023.
• The 4-year median for Shares Outstanding (Diluted Average) is $31.5 million (2024), against an average of $24.3 million.
• Across the five-year window, Shares Outstanding (Diluted Average) jumped 1845.25% in 2024 and grew 10.09% in 2025, its largest moves.
• ArriVent BioPharma's Shares Outstanding (Diluted Average) stood at $2.1 million in 2023, then jumped by 1369.88% to $31.5 million in 2024, then grew by 22.22% to $38.5 million in 2025, then gained by 17.17% to $45.1 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $45.1 million (Q1 2026), $38.5 million (Q4 2025), and $37.0 million (Q3 2025), per Business Quant data.